- MediClear PreOp is a novel pre-operative film drape designed to reduce the level of bacteria on a patient’s skin before a surgical procedure.
Frost & Sullivanis a global research organization that monitors more than 300 industries and 25,000 companies.
Surgical site infection (“SSI”) is one of the most common post-operative complications and the most frequently reported healthcare-associated infection. SSI occurs in 3 to 5% of the estimated 234.2 million annual surgical procedures worldwide and is fatal in about 3% of these cases.1 The product’s polyurethane barrier film acts as a protective barrier to isolate a procedural site from external contamination. Its silicone adhesive provides a rapid bactericidal and fungicidal effect against a broad spectrum of microorganisms, averaging a 99.9% reduction in microorganisms after 10 minutes and a 99.99% reduction after 30 minutes, and preventing their regrowth for up to seven days during wear. MediClear PreOp is breathable and transparent, and is available in three sizes to protect skin for common procedures, including cardio-thoracic, orthopedic, and plastic surgeries.
"The recognition by
“Frost & Sullivan believes that the product’s capability to maintain antimicrobial activity equal to or better than current best practices, in addition to the benefits of ease of use and a reduced clinical workload, will result in further savings in terms of improved clinician efficiency, higher staff satisfaction, and improved patient outcomes,” said
For the New Product Innovation Award,
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This news release contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements are often, but not always, identified by the use of words such as "seek", "anticipate", "plan, "estimate", "expect", "intend" and statements that an event or result "may", "will", "should", "could" or "might" occur or be achieved and other similar expressions. These forward-looking statements involve risk and uncertainties, including the difficulty in predicting product approvals, acceptance of and demands for new products, the impact of the products and pricing strategies of competitors, delays in developing and launching new products, the regulatory environment, fluctuations in operating results and other risks, any of which could cause results, performance, or achievements to differ materially from the results discussed or implied in the forward-looking statements. Many risks are inherent in the industry; others are more specific to the Company. Investors should consult the Company's ongoing quarterly filings for additional information on risks and uncertainties relating to these forward-looking statements. Investors should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update or alter any forward-looking statements whether as a result of new information, further events or otherwise.
1 Frost & Sullivan Report – 2018 North American Surgical Site Infection Prevention New Product Innovation Award.